Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 9 - Caught on Camera

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

MarketBeat · Feb 19, 2025

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Barchart · Feb 6, 2025

What has the UK Covid inquiry learned so far about vaccines and treatments?

In fourth part of the inquiry, questons were asked about vaccine trials, procurement and the UK’s preparedness for future pandemics

The Guardian - UK · Jan 31, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

Barchart · Jan 27, 2025

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

Fortune · Jan 23, 2025

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

MarketBeat · Jan 22, 2025

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

International Business Times UK · Jan 14, 2025

Read news from The Economist, FT, and more,
with one subscription

Moderna surprises the Street by predicting a bigger-than-expected sales drop

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year

The Independent UK · Jan 13, 2025

Moderna Stock Poised For Another Drop After Shaving Nearly $1 Billion Off Earnings Estimates

The drug maker's stock plunged more than 17% in pre-market trading after slashing its sales outlook.

International Business Times · Jan 13, 2025

No norovirus vaccine exists—yet. Moderna says it’s ‘one step closer,’ and you may be eligible to participate in its ongoing clinical trial

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Fortune · Jan 11, 2025

Stock Market Today: Stocks End Mixed After FOMC Minutes

The minutes from the December Fed meeting signaled central bankers' uncertainty over potential Trump administration policies.

Kiplinger · Jan 8, 2025

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

Kiplinger · Jan 8, 2025

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

Barchart · Jan 8, 2025

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

MarketBeat · Jan 8, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune · Dec 16, 2024

Pediatric RSV vaccine trial paused by Moderna amid safety concerns

Five infants required hospitalization, with one needing mechanical ventilation.

Barchart · Dec 16, 2024

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

The Guardian - AU · Dec 10, 2024

Moderna’s mRNA vaccines to be exempt from advisory committee scrutiny under $2bn Morrison-era deal

Exclusive: Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems

AAP · Dec 4, 2024

New vaccine facility a shot in the arm for Australians

Up to 100 million mRNA jabs will be made at Moderna's new plant, with a promise Australia will always be at the top of the vaccine queue for locally-made jabs.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Nov 21, 2024

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

MarketBeat · Nov 21, 2024

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

MarketBeat · Nov 16, 2024

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

Barchart · Nov 15, 2024

Stocks Settle Sharply Lower on the Outlook for Slower Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -1.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.40%. Stocks retreated Friday, with the S&P 500 and Nasdaq 100 falling to 1-1/2 week...

Barchart · Nov 15, 2024

Stocks Tumble as Hawkish Fed and Strong US Economic News Boosts Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -1.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.03%. Stocks today extended Thursday’s decline, with the S&P 500 and the Dow Jones Industrials...

The Guardian - UK · Nov 15, 2024

Pharma shares hit as Trump picks RFK Jr to lead health department

Choice of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK

Barchart · Nov 12, 2024

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

1 … 8 9 10 11

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.